PTSH: Current week will be very exciting!

Golden-Cross to come at the 3rd of March!?! Should cause a huge run in combination with the expected NEWS

Volume is increasing...good sign!

PTSH: Current week will be very exciting!

Golden-Cross to come at the 3rd of March!?! Should cause a huge run in combination with the expected NEWS

Volume is increasing...good sign!

PTSH: Current week will be very exciting!

Golden-Cross to come at the 3rd of March!?! Should cause a huge run in combination with the expected NEWS

Volume is increasing...good sign!

PTSH: Charttechnical Update/Development

Breakout of the ascending triangel has occured to the rules.

Price is moving forward to .0021$ by breaking several small resistance...

If we will break .0021 it will move rapidly to the older high at .0048$:

If the pretended szenario will happen, we will see a very bullish momentum: A STRAIGHT "GOLDEN CROSS" will happen at the beginning of March (Tuesday - Wedenesday). This will fasten the upmove dramatically!

Overall appraisal: Volume and indicators are moving in a bullish range. This is creating much hope for an ascending shareprice next week!

Could anybody imagine what will happen if we receive a PR at the beginning of next week (OTC-approval of its subsidiary DBYC, signing of a big governmental contract, software-licence-contract)????

PTSH: Charttechnical Update/Development

Breakout of the ascending triangel has occured to the rules.

Price is moving forward to .0021$ by breaking several small resistance...

If we will break .0021 it will move rapidly to the older high at .0048$:

If the pretended szenario will happen, we will see a very bullish momentum: A STRAIGHT "GOLDEN CROSS" will happen at the beginning of March (Tuesday - Wedenesday). This will fasten the upmove dramatically!

Overall appraisal: Volume and indicators are moving in a bullish range. This is creating much hope for an ascending shareprice next week!

Could anybody imagine what will happen if we receive a PR at the beginning of next week (OTC-approval of its subsidiary DBYC, signing of a big governmental contract, software-licence-contract)????

PTSH: Charttechnical Update/Development

Breakout of the ascending triangel has occured to the rules.

Price is moving forward to .0021$ by breaking several small resistance...

If we will break .0021 it will move rapidly to the older high at .0048$:

If the pretended szenario will happen, we will see a very bullish momentum: A STRAIGHT "GOLDEN CROSS" will happen at the beginning of March (Tuesday - Wedenesday). This will fasten the upmove dramatically!

Overall appraisal: Volume and indicators are moving in a bullish range. This is creating much hope for an ascending shareprice next week!

Could anybody imagine what will happen if we receive a PR at the beginning of next week (OTC-approval of its subsidiary DBYC, signing of a big governmental contract, software-licence-contract)????

The reason about PTSH upmove:

- Approval of its subsidiary DBYC is expected to come very soon. This would cause a huge hype as DBYC is generating yearly revenues of nearly 1,500,000$ and nearly touching the break-even.

- Big governmental contracts are in the final stage of negotiation which would cause revenues in a heith of several million-

- several nationalwide-contracts are also in the final stage of negotiation

- new developed software is reducing costs by enlarging the productivity

- new software could also be used for other business-branches/ softwarelicence-agreements should be signed in the next few time.

This stock with all its market-opportunities could really easy exceed a marketcapitalization of 10,000,000$.

Note: currently we are just reaching a marketcap of nearly 2,025,000$ while generating yearly revenues of 1,500,000$ showing steadily reduced losses. outstanding shares just showing 1,350,000,000 shares!

The reason about PTSH upmove:

- Approval of its subsidiary DBYC is expected to come very soon. This would cause a huge hype as DBYC is generating yearly revenues of nearly 1,500,000$ and nearly touching the break-even.

- Big governmental contracts are in the final stage of negotiation which would cause revenues in a heith of several million-

- several nationalwide-contracts are also in the final stage of negotiation

- new developed software is reducing costs by enlarging the productivity

- new software could also be used for other business-branches/ softwarelicence-agreements should be signed in the next few time.

This stock with all its market-opportunities could really easy exceed a marketcapitalization of 10,000,000$.

Note: currently we are just reaching a marketcap of nearly 2,025,000$ while generating yearly revenues of 1,500,000$ showing steadily reduced losses. outstanding shares just showing 1,350,000,000 shares!

PTSH !! 0,0018 !!

PTSH - Chartreview - closed at .0013$ (+ 18.18%)

OUTBREAK IN PROGRESS:

Volume increasing!

Created a higher high and a higher low

looking pretty fine:

PTSH - Chartreview - closed at .0013$ (+ 18.18%)

OUTBREAK IN PROGRESS:

Volume increasing!

Created a higher high and a higher low

looking pretty fine:

PTSH - Chartreview - closed at .0013$ (+ 18.18%)

OUTBREAK IN PROGRESS:

Volume increasing!

Created a higher high and a higher low

looking pretty fine:

PTSH Volume get higher

have a look at PTSH

PTSH rocks

PTSH - Charttechnical update!

Should be the week of decision!

Chart showing a bullish development.

All SMAs turning to crossing-areas - very bullish!

PTSH - Charttechnical update!

Should be the week of decision!

Chart showing a bullish development.

All SMAs turning to crossing-areas - very bullish!

PTSH Breakout? CHART

PTSH Chart UPDATE

PTSH Chart

PTSH Breakout this week ?!?!

PTSH Breakout this week!?!?

joelu it WILL move

playyyer

PTSH NEWS


News for 'PTSH' - (Disability Access Consultants, Inc. Announces 2009 Fourth Quarter Revenues)

PTSH News -- Disability Access Consultants, Inc. Announces 2009 Fourth Quarter Revenues.

Wednesday, February 10, 2010 6:33 AM

Scottrade.com
This email is compliments of Scottrade.com

News for 'PTSH' - (Disability Access Consultants, Inc. Announces 2009 Fourth Quarter Revenues)

LAS VEGAS, Feb 10, 2010 /PRNewswire via COMTEX/ -- Disability Access
Corporation (Pink Sheets: DBYC) a subsidiary of PTS, Inc. (OTC Bulletin Board:
PTSH), announced today that Disability Access Consultants, Inc.(DAC), a wholly
owned subsidiary of Disability Access Corporation today announced unaudited
revenues for the fourth quarter of 2009 in the amount of $565,000 which
represents an eighty percent (80%) increase compared to 2008 fourth quarter
revenues of $313,000, for an increase of $252,000 over the previous year's
quarter. On an annual basis DAC unaudited revenues for 2009 were $1,456,000
which compared to 2008 annual revenues of $1,418,000 represents a year to year
increase of $38,000 for a three percent (3%) increase.

Though the company is pleased that revenues grew in spite of the weakness in the
economy, the pace of growth was impacted by the trepidation in the existing and
prospective client base over public and private funding for various programs and
projects. The company believes that its revenue growth in a "very down economy"
is reflective of both the need and demand for the company's services as well as
the company's service and product integrity.

About Disability Access Consultants, Inc. (DAC)

Disability Access Consultants, Inc., (DAC) a wholly own subsidiary of Disability
Access Corporation (Pink Sheets: DBYC - News) conducts facility inspections,
policy reviews and program analyses in addition to a comprehensive continuum of
other compliance services. Over 54 million people in the US have a disability, a
number equal to 20% of the population. The Americans with Disabilities Act of
1990 requires all organizational entities, public or private, with more than 15
employees, to provide equal access for individuals with disabilities. It's
estimated that there are more than seven million sites at risk across the United
States. Please visit: www.adaconsultants.com.

Safe Harbor Statement:

Except for historical information contained herein, the statements in this news
release are forward-looking statements that involve risks and uncertainties and
are made pursuant to the safe harbor provisions of the Private Securities Reform
Act of 1995. Forward-looking statements involve known and unknown risks and
uncertainties, which may cause the company's actual results in the future
periods to differ materially from forecasted results.

SOURCE Disability Access Corporation



www.prnewswire.com


Copyright (C) 2010 PR Newswire. All rights reserved

-0-

Generex Inks Deal With Sanofi-Aventis for Insulin Supply

December 09, 2009


WORCESTER, Mass., Dec 9, 2009 (GlobeNewswire via COMTEX News Network) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has signed a long-term agreement with Sanofi-Aventis Deutschland GmbH (www.sanofi-aventis.com) for the manufacture and supply of recombinant human insulin crystals for commercial and clinical trial use in Generex's proprietary buccal insulin spray product, Generex Oral-lyn(TM). The financial terms of the arrangement were not disclosed.

The API (Active Pharmaceutical Ingredient) Supply agreement will provide the Company with a source of insulin for major regulatory markets including the United States and Canada and a number of other regions where the Company is pursuing regulatory approvals for Generex Oral-lyn(TM).

The Company's regulatory team will commence the process of updating any and all current submissions to include sanofi-aventis' insulin crystal which will be formulated in the Generex Oral-lyn(TM) commercial product.

"We are very pleased to have entered into this long-term supply agreement for insulin crystal," said Anna Gluskin, Generex's President and Chief Executive Officer. "It solidifies one of our key product components which will assist in the smooth transition into commercialization of our flagship product, Generex Oral-lyn(TM), into major markets where we will seek to establish a new paradigm for the treatment of diabetes."

Thanks to almost a century of chemical, pharmaceutical, medical and industrial research, led by Hoescht and its successors, sanofi-aventis can today claim its place as the historic leader in both the production of insulin and the treatment of diabetes.

At the end of the 1990s, the site of sanofi-aventis in Frankfurt, Germany, formerly Hoechst, developed pilot units and large-scale production of human recombinant insulin from a genetically modified Escherichia Coli strain.

As part of the commercial offer provided by the Commercial and External Partnership Industrial Affairs (CEPIA) at sanofi-aventis for human recombinant insulin, Generex, in cooperation with sanofi-aventis, will benefit from sanofi-aventis' ability and expertise to offer quality and regulatory support.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Study Finds Generex Oral-lyn(TM) is Safe, Effective, May Reduce Complications of Insulin-Dependent Diabetes
Review of Clinical Trials of Oral Insulin Published This Month in Diabetes, Obesity and Metabolism

WORCESTER, Mass., Dec. 3, 2009 (GLOBE NEWSWIRE) -- Published in the journal Diabetes, Obesity and Metabolism, an independent review of clinical trials of Generex Oral-lyn(TM) shows that the oral insulin spray has a faster onset of action and shorter duration of action than insulin delivered subcutaneously.

"The ease of use of the insulin spray formulation may increase patient acceptance and treatment compliance, thereby potentially reducing complications and improving quality of life for patients with insulin-dependent diabetes," the review authors wrote.

Generex Oral-lyn(TM) is the flagship product of Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn(TM) does not have pulmonary side effects. It is safely and efficiently delivered in pain-free, standardized doses via the Company's proprietary RapidMist(TM) device, which looks like a simple asthma inhaler, but provides complete absorption through the buccal mucosa (lining of the mouth) with no deposit in the lungs.

International Diabetes Federation guidelines identify glycemic control as a crucial factor in management of the disease, yet ensuring insulin therapy compliance can be problematic when up to one-quarter of people with diabetes have needle anxiety (Diabetes Res. Clin. Pract. 1999;46:239-46).

"Patients who are needle averse face a serious barrier to their recommended treatment," warns Generex President and CEO Anna E. Gluskin. "Generex Oral-lyn(TM) promises a pain-free alternative to injectable insulin, which is good news especially for older patients and children who find needles uncomfortable."

The clinical trials of Generex Oral-lyn(TM) include patients with Type 1 and Type 2 diabetes. Incidence of Type 1 diabetes is growing by 3 percent per year in children and adolescents, and at an alarming 5 percent per year among pre-school children. It is estimated that 70,000 children under the age of 15 develop Type 1 diabetes each year -- a rate of almost 200 children each day. Currently, an estimated 440,000 children globally live with Type 1 diabetes. Type 2 diabetes was once seen as a disease of adults, but is also growing at alarming rates in children and adolescents.

"Review of clinical trials: update on oral insulin spray formulation" was authored by Paolo Pozzilli, MD, Director of Endocrinology and Diabetes, University Campus Bio-Medico, Rome; Philip Raskin, MD, Department of Internal Medicine, Southwestern Medical Center, Dallas; and Christopher G. Parkin, MS, Carmel, Indiana. The article was published online this month in advance of print publication in Diabetes, Obesity and Metabolism. The article is available at http://tr.im/DOM09.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831

PTSH - consolidation on a high level, with a real bullish flavor!

http://easyupload.hoerby.org/up/6682132121637847493.png


http://easyupload.hoerby.org/up/951481542084061918.png

These are the things to come:

from PR dated 21st of July:

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++

..."Though the economic downturn did have an effect on number businesses and various public entities, we have noticed a significant increase in request for proposals and demand for services. While the second quarter was lower than anticipated, the third quarter is shaping up to be our busiest ever, and we expect to be completing contract negotiations with a number of new clients over the next few weeks," stated Barbara Thorpe, DAC's President.

Separately, DAC has secured office facilities in the Washington D.C. area. The Washington D.C. office is being opened to further facilitate DAC's business plan....

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++

This break indicating up-coming governmental contracts!

http://www.quotemedia.com/results.php?qm_symbol=PTSH


Furthermore the PR dated the 12th of August:

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++

...Barbara Thorpe, DAC's President, commenting on these recently announced agreements and other pending agreements stated, "Though we have accepted a number of agreements recently, we still have a number of large pending agreements under negotiation. Also due to the demands for our services we are in the final stages of planning with regards to establishing a subscription program for the third party use of our software. If we go forward with this model we would have a fee plus percentage of gross revenue participation agreement with our subscribers which would be highly incremental and the ultimate benefit of our company. The challenge we currently have, is probably the best type of challenge to have, which is that demand for our services currently exceeds our capacity, so accordingly we are continuing to evolve new processes and methods to capitalize on our growth and revenue opportunities." ...

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

This is indicating not only the up-coming break-even but a huge large spread of PTSH´s activities! jonit-venture to solve the exceeding capacity-problems?

PTSH - consolidation on a high level, with a real bullish flavor!

http://easyupload.hoerby.org/up/6682132121637847493.png


http://easyupload.hoerby.org/up/951481542084061918.png

These are the things to come:

from PR dated 21st of July:

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++

..."Though the economic downturn did have an effect on number businesses and various public entities, we have noticed a significant increase in request for proposals and demand for services. While the second quarter was lower than anticipated, the third quarter is shaping up to be our busiest ever, and we expect to be completing contract negotiations with a number of new clients over the next few weeks," stated Barbara Thorpe, DAC's President.

Separately, DAC has secured office facilities in the Washington D.C. area. The Washington D.C. office is being opened to further facilitate DAC's business plan....

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++

This break indicating up-coming governmental contracts!

http://www.quotemedia.com/results.php?qm_symbol=PTSH


Furthermore the PR dated the 12th of August:

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++

...Barbara Thorpe, DAC's President, commenting on these recently announced agreements and other pending agreements stated, "Though we have accepted a number of agreements recently, we still have a number of large pending agreements under negotiation. Also due to the demands for our services we are in the final stages of planning with regards to establishing a subscription program for the third party use of our software. If we go forward with this model we would have a fee plus percentage of gross revenue participation agreement with our subscribers which would be highly incremental and the ultimate benefit of our company. The challenge we currently have, is probably the best type of challenge to have, which is that demand for our services currently exceeds our capacity, so accordingly we are continuing to evolve new processes and methods to capitalize on our growth and revenue opportunities." ...

+++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

This is indicating not only the up-coming break-even but a huge large spread of PTSH´s activities! jonit-venture to solve the exceeding capacity-problems?

[bPTSH close very nice. smells like breakout

PTSH seems very bullish

GNBT nice move nice volume

PTSH rocks

lol

Hello Prinz "Hohlbirne"

nice to see you here.
It seems like you are very interested in this stock.
So buy it and feel lucky.

playyyer

PTSH Breakout

PTSH NO Joke - Breakout

PTSH Outbreak

Hi froggy "sorry" freddy

nice to hear something about you.
I hope to get some updates the next few days.

best wishes
playyyer

Video Stream Engages $46 Billion Video Surveillance Market
FORT LAUDERDALE, Fla., Sept. 15, 2008 (GLOBE NEWSWIRE) -- Aventura Holdings, Inc. (OTCBB:AVNT) through its wholly owned subsidiary Video Stream, Inc. engages the video surveillance market which is one of the nation's fastest growing industry groups.

ABI Research believes that the video surveillance market is poised for explosive growth to a remarkable $46 billion in 2013. Homeland Security Research, a market research company, predicts that homeland security industry spending will grow to $170 billion per year by 2015.

Technology in this sector is evolving at warp speed and Video Stream is positioned to become a leader.

Since Sept. 11, 2001, the U.S. Department of Homeland Security and its agencies have paid private contractors at least $130 billion, an analysis of federal databases shows. The top ten contractors won at least $65 billion, or roughly half, of that. General Electric's InVision heads the list followed by the likes of IBM, L-3 Communications and Honeywell, according to a computer analysis of federal contract awards and based on conservative estimates from the Federal Procurement Data System. The other half or roughly $65 billion was awarded to more than 3,200 firms.

Other government agencies, from the Defense and Justice Departments to county governments across the USA, are also pouring money into the same market. In fact, Homeland Security receives just half of the federal government's spending on such projects, according to US budget documents. Additionally, private companies are also spending big to protect themselves.

To form the basis of future workings with security dealers and integrators, Video Stream products unify video surveillance analog and internet protocol (IP) worlds thereby enabling higher resolutions, convergence onto existing IP cabling infrastructure, eases routing over long distances especially on multi-building sites, reduces space requirements, enables progressive scanning rendering clearer images, supports different streaming media and compression formats to relieve transmission bandwidth and data storage requirements (MJPEG, MPEG4, H.264) and provides a thin transport layer for remote storage. Most important, if the network is unified, it can be managed from one place.

About Aventura Holdings, Inc.

Through its wholly owned subsidiaries, Aventura Holdings provides enterprise video streaming and surveillance products and custom infrastructure solutions. Additional information can be found on the Company's website: www.Aventura-Holdings.com

Safe Harbor

This press release may contain "forward-looking statements." Although Aventura Holdings, Inc. believes any such statements are based on reasonable assumptions, there is no assurance that actual outcomes will not be materially different. Aventura Holdings, Inc. assumes no obligation to update those statements to reflect actual results, changes in assumptions and other factors. The forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those projected. Additional information that could lead to material changes in performance is contained in filings with the Securities and Exchange Commission.

CONTACT: Aventura Holdings, Inc.
Craig A. Waltzer
(305) 937 2000



Source: GlobeNewswire (September 15, 2008 - 7:01 AM EDT)

News by QuoteMedia

or tomorrow
maybe next month
possible next year